References:
[1] Henter JI, Horne A, Aricó M, et al. HLH-2004: Diagnostic and
therapeutic guidelines for hemophagocytic
lymphohistiocytosis. Pediatr Blood Cancer . 2007;48(2):124-131.
doi:10.1002/pbc.21039
[2] Lehmberg K, Nichols KE, Henter JI, et al. Consensus
recommendations for the diagnosis and management of hemophagocytic
lymphohistiocytosis associated with malignancies. Haematologica .
2015;100(8):997-1004. doi:10.3324/haematol.2015.123562
[3] AALL1732: A Phase 3 Randomized Trial of Inotuzumab Ozogamicin
for Newly Diagnosed High-Risk B-ALL; Risk Adapted Post-Induction Therapy
for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated
B-LLy
[4] Bracaglia C, Marafon DP, Caiello I, et al. High levels of
interferon-gamma (IFNγ) in macrophage activation syndrome (MAS) and
CXCL9 levels as a biomarker for IFNγ production in MAS. Pediatr
Rheumatol Online J . 2015;13(Suppl 1):O84. Published 2015 Sep 28.
doi:10.1186/1546-0096-13-S1-O84
[5] Locatelli F, Jordan MB, Allen C, et al. Emapalumab in Children
with Primary Hemophagocytic Lymphohistiocytosis. N Engl J Med .
2020;382(19):1811-1822. doi:10.1056/NEJMoa1911326
[6] AALL1231: A Phase III Randomized Trial Investigating Bortezomib
on a Modified Augmented BFM (ABFM) Backbone in Newly Diagnosed T-
Lymphoblastic Leukemia (T-ALL) and T- Lymphoblastic Lymphoma (T-LLy)
[7] Wang J, Wang Y, Wu L, et al. Ruxolitinib for refractory/relapsed
hemophagocytic lymphohistiocytosis. Haematologica .
2020;105(5):e210-e212. doi:10.3324/haematol.2019.222471
[8] van Enckevort FH, Netea MG, Hermus AR, et al. Increased
susceptibility to systemic candidiasis in interleukin-6 deficient
mice. Med Mycol . 1999;37(6):419-426.
doi:10.1046/j.1365-280x.1999.00247.x
[9] Tabata C, Tabata R. Possible prediction of underlying lymphoma
by high sIL-2R/ferritin ratio in hemophagocytic syndrome. Ann
Hematol . 2012;91(1):63-71. doi:10.1007/s00277-011-1239-7